@article{ee6c47aa6d1b4445b4b8a913f9d2e1f7,
title = "No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial",
abstract = "In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.",
keywords = "ART simplification, ART switch, Dolutegravir, Lamivudine, Residual viremia",
author = "Li, {Jonathan Z.} and Sax, {Paul E.} and Marconi, {Vincent C.} and Jesse Fajnzylber and Baiba Berzins and Nyaku, {Amesika N.} and Fichtenbaum, {Carl J.} and Timothy Wilkin and Benson, {Constance A.} and Koletar, {Susan L.} and Ramon Lorenzo-Redondo and Taiwo, {Babafemi O.}",
note = "Funding Information: This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU). V.C.M., C.J.F., C.A.B., T.W., S.L.K., J.C., J.Z.L., and P.E.S. have received grant funding for this study to their institutions through NU from ViiV/GSK. V.C.M. has received funding from the Emory CFAR (P30AI050409). Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",
year = "2019",
month = mar,
doi = "10.1093/ofid/ofz056",
language = "English (US)",
volume = "6",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "3",
}
